Macy's: A Year in Review and a Look Ahead

Macy's has materially outperformed in 2025, with the share price up 36.3% through Dec. 16 and a total return of 43.3% (including dividends), versus the S&P 500's 14.8% price gain. Management's turnaround—store closures, store revamps, service improvements and a shift to higher-income customers via Bloomingdale's and Bluemercury—has helped comps improve (owned+licensed+marketplace comps up 3.2% in fiscal Q3 to Nov. 1; Bloomingdale's comps rose ~9% in the latest quarter). Key risks to monitor into 2026 are housing-price momentum, equity market strength and macro indicators (unemployment, consumer confidence, CPI) that could dent high-income discretionary spending.

Analysis

Market structure: Macy’s (M) is capturing share from lower-priced peers by shifting mix toward Bloomingdale’s and Bluemercury; Bloomingdale’s +9% comp vs Macy’s overall +3.2% signals concentrated upside in premium assortments and brand partnerships (licensing/marketplace). Suppliers of higher-end apparel, beauty vendors and private-label partners stand to gain margin leverage; off-price discounters could be relatively pressured if high-income spend remains strong.

Risk assessment: Key tail risks are a macro shock (S&P down ≥20% within 6 months), housing prices down >5% YoY, or unemployment >6%—any would likely reverse high-end discretionary strength and knock comps into negative territory. Short-term (days–weeks) risk centers on holiday sell-through and returns volatility; medium-term (3–6 months) hinges on Q4 comps and inventory digestion; long-term (12–24 months) depends on successful store rationalization and marketplace execution.

Trade implications: Favor idiosyncratic long exposure to M while hedging broad retail beta: establish a 2–3% portfolio long in M and pair with a 1:1 short in XRT (retail ETF) to isolate Macy’s execution premium. Use options to express asymmetric risk: buy 6–9 month calls ~15–20% OTM or sell cash-secured puts ~10% below current price to collect premium and set a disciplined entry; target 12-month upside 20–30% with a 12% stop if comps slip below 0%.

Contrarian angles: Consensus overlooks optionality in Macy’s marketplace/licensing and Bluemercury’s scalable margins—these could add 200–400 bps to gross margin if penetration rises meaningfully. Countervailing risk is alienating core middle-income shoppers; monitor average ticket (+/-) and traffic trends — if ticket rises >4% while traffic holds, the turnaround is real; if ticket rises but traffic falls >5%, the strategy is likely unsustainable.

Key Decisions for Investors

• Establish a 2–3% long position in Macy’s (M) within 1–2 weeks to capture premium-mix momentum; size as idiosyncratic bet with portfolio stop-loss at -12% or if Macy’s owned-plus-licensed-plus-marketplace comps fall below 0% in the next quarter.
• Initiate a pair trade: long $1 of M vs short $1 of XRT (ETF) for 3–6 months to isolate Macy’s outperformance; unwind if Macy’s Bloomingdale’s comps decline to <+2% or XRT outperforms by >8% in 30 days.
• Use options to limit downside: buy 6–9 month calls ~15–20% OTM (calendar anchored to Q4 print) sized 0.5–1% notional, or sell cash-secured puts ~10% below current price to acquire shares at a discount while collecting premium; target 20–30% upside in 12 months.
• Reduce or avoid exposure to mass-market, low-margin retailers (e.g., select dollar-store and discount names) by 1–2% of portfolio and rotate into premium discretionary and specialty beauty names if Bloomingdale’s comps remain >7% next quarter.
• Monitor three 30–60 day triggers before scaling up: 1) U.S. unemployment trend (watch for >6%), 2) housing price momentum (watch for >5% YoY decline), and 3) Macy’s month-end comp cadence—if any trigger fires, reduce M exposure by half within one week.